Search Results - "Danon, Uri"

Human Muscle Progenitor Cells Overexpressing Neurotrophic Factors Improve Neuronal Regeneration in a Sciatic Nerve Injury Mouse Model by Guy, Reut, Grynspan, Frida, Ben-Zur, Tali, Panski, Avraham, Lamdan, Ron, Danon, Uri, Yaffe, David, Offen, Daniel

“…The peripheral nervous system has an intrinsic ability to regenerate after injury. However, this process is slow, incomplete, and often accompanied by…”
Get full text

2052-LB: Semaglutide Depot, a Long-Acting Injection of Semaglutide Administered Once Every Four Weeks, Demonstrates Similar Efficacy and PK Profile to Daily Semaglutide Administration by Rubnov, Shai, Zats, Galina, Kimelman, Nadav Bleich, Popper, Laura, Danon, Uri, Marom, Ehud

“…Introduction and Objectives: Semaglutide Depot consists of extended-release microspheres administered every 28 days, aiming to provide improved dosing regimen…”
Get full text

GA Depot (Long-acting IM Injection of Glatiramer Acetate) Presents Improved Safety and Tolerability Features: Results from a Multinational, Double-blind, Placebo-controlled Phase III Study in Subjects with Relapsing Forms of Multiple Sclerosis (P8-6.018) by Miller, Aaron, Popper, Laura, Kolb, Hadar, Kimelman, Nadav, Rubnov, Shai, Danon, Uri, Marom, Ehud

“…Abstract only…”
Get full text

Results of a Phase III, Multinational, Double-blind, Placebo-controlled Study in Subjects with Relapsing Forms of Multiple Sclerosis (RMS) to Assess the Efficacy, Safety, and Tolerability of GA Depot, a Long-Acting IM Injection of Glatiramer Acetate, Administered Once Every Four Weeks (P6-3.014) by Miller, Aaron, Popper, Laura, Berger, Joseph, Kimelman, Nadav, Rubnov, Shai, Danon, Uri, Marom, Ehud

“…Abstract only…”
Get full text

Oral Administration of a Novel Small Molecule Blocks the BMP Canonical and the Non-canonical BMP2, BMP4, and BMP5 Signaling Pathways Ameliorates EAE Through Oligodendrogenesis Remyelination and Preservation of Axonal Integrity and Reduces Astrogenesis (P7-6.015) by Golan, Maya, Benhamou, Moshe, Fainberg, Karin, Kimelman, Nadav Bleich, Rubnov, Shai, Danon, Uri, Marom, Ehud, Karni, Arnon

“…Abstract only…”
Get full text

Specific Blockade of Bone Morphogenetic Protein-2/4 induces Oligodendrogenesis and Remyelination in Demyelinating Disorders (2042) by Fainberg-Mausner, Karin, Benhamou, Moshe, Golan, Maya, Kimelman, Nadav Bleich, Danon, Uri, Marom, Ehud, Karni, Arnon

“…Abstract only…”
Get full text

Specific Blockade of Bone Morphogenetic Protein-2/4 Induces Oligodendrogenesis and Remyelination in Demyelinating Disorders by Mausner-Fainberg, Karin, Benhamou, Moshe, Golan, Maya, Kimelman, Nadav Bleich, Danon, Uri, Marom, Ehud, Karni, Arnon

“…Oligodendrocyte precursor cells (OPCs) are present in demyelinated lesions of multiple sclerosis (MS) patients. However, their differentiation into functional…”
Get full text

Glatiramer Acetate Depot (Extended-Release) Phase IIa Study in Patients with Primary Progressive Multiple Sclerosis: Safety and Efficacy Snapshot (P7-4.001) by Flechter, Shlomo, Popper, Laura, Kimelman, Nadav Bleich, Rubnov, Shai, Danon, Uri, Marom, Ehud, Milo, Ron, Gilad, Ronit, Weller, Boaz, Vaknin-Dembinsky, Adi, Hellman, Mark, Shifrin, Alla, Karni, Arnon

“…Abstract only…”
Get full text

Glatiramer Acetate Depot (extended-release) phase IIa study in patients with Primary Progressive Multiple Sclerosis: safety and efficacy snapshot (1911) by Flechter, Shlomo, Popper, Laura, Demender, Inna, Kimelman, Nadav Bleich, Rubnov, Shai, Danon, Uri, Marom, Ehud, Milo, Ron, Gilad, Ronit, Weller, Boaz, Vaknin-Dembinsky, Adi, Hellmann, Mark, Karni, Arnon

“…Abstract only…”
Get full text

Five Years Analysis of anti-Glatiramer Acetate (GA) Antibodies in Patients with Relapsing Remitting Multiple Sclerosis Treated with GA Depot (P5-4.010) by Flechter, Shlomo, Miller, Ariel, Popper, Laura, Kimelman, Nadav Bleich, Rubnov, Shai, Danon, Uri, Marom, Ehud, Milo, Ron, Chapman, Joab, Shifrin, Alla, Gilad, Ronit, Hoffmann, Chen, Ben Hur, Tamir, Karussis, Dimitrios, Karni, Arnon

“…Abstract only…”
Get full text

Glatiramer Acetate Depot (extended-release) phase IIa study in patients with primary progressive multiple sclerosis: safety and efficacy snapshot (1956) by Flechter, Shlomo, Popper, Laura, Kimelman, Nadav Bleich, Demender, Inna, Rubnov, Shai, Danon, Uri, Marom, Ehud, Milo, Ron, Gilad, Ronit, Weller, Boaz, Vaknin-Dembinsky, Adi, Hellmann, Mark, Karni, Arnon

“…Abstract only…”
Get full text

Glatiramer Acetate Depot (extended-release) phase IIa study in patients with relapsing remitting multiple sclerosis: safety, tolerability and efficacy (No Evidence of Disease Activity) subpopulation three-years analysis (1936) by Flechter, Shlomo, Miller, Ariel, Popper, Laura, Kimelman, Nadav Bleich, Rubnov, Shai, Danon, Uri, Marom, Ehud, Milo, Ron, Chapman, Joab, Shifrin, Alla, Gilad, Ronit, Hoffmann, Chen, Karussis, Dimitrios, Karni, Arnon

“…Abstract only…”
Get full text

Pre-Clinical Studies and Evaluation of Treatment Need of Glatiramer Acetate Depot (Long Acting Injection) (P5.314) by Bleich Kimelman, Nadav, Rubnov, Shai, Danon, Uri, Marom, Ehud, Miller, Ariel

“…Abstract only…”
Get full text

Glatiramer Acetate Depot (Extended-Release) Phase IIa Study in Patients with Relapsing Remitting Multiple Sclerosis: Safety, Tolerability and Efficacy (No Evidence of Disease Activity) Two-Years Analysis (P3.2-052) by Flechter, Shlomo, Miller, Ariel, Popper, Laura, Kimelman, Nadav Bleich, Rubnov, Shai, Danon, Uri, Marom, Ehud, Milo, Ron, Chapman, Joab, Shifrin, Alla, Gilad, Ronit, Hoffmann, Chen, Karussis, Dimitrios, Karni, Arnon

“…Abstract only…”
Get full text

Glatiramer Acetate Depot (extended-release) Phase IIa one-year study in patients with Relapsing-remitting Multiple Sclerosis: Safety, tolerability and efficacy – NEDA Analysis (P6.359) by Miller, Ariel, Popper, Laura, Danon, Uri, Kimelman, Nadav Bleich, Rubnov, Shai, Marom, Ehud, Chapman, Joab, Shifrin, Alla, Gilad, Ronit, Karussis, Dimitrios, Milo, Ron, Hoffmann, Chen, Flechter, Shlomo, Karni, Arnon

“…Abstract only…”
Get full text